MyVisionTest News Archive

Displaying news items tagged with adverse drug effects (More tags »)
SELECT PAGE
First <<  1 2 3 4   >> Last

Intravitreal injection
Nov 18, 2009
Vascular endothelial growth factor (VEGF) ligands and their receptors are essential for development and for a wide variety of physiologic functions through adulthood, including visual function. Given the ubiquitous physiologic role of VEGF, evaluation of potential safety risks associated with nonspecific inhibition of VEGF-A and other VEGF-related...

Full Article


fluorescein angiography
Nov 16, 2009
A study investigating the utility of fluorescein skin testing to predict the risk of anaphalaxis to intravenous fluorescein angiography (IVFA) concludes that most adverse reactions to fluorescein are mild and not attributed to immunological mechanisms. IVFA is used extensively for the management of vitreoretinal diseases. However, IVFA is not...

Full Article


Avastin
Oct 26, 2009
How different compounding pharmacies prepare doses of Avastin may lead to differences in high molecular weight adducts that may plug outflow pathways or cause an immunologic response that leads to IOP spikes, a speaker said at American Academy of Ophthalmology. "By no means am I saying that Avastin is doing something to the trabecular meshwork...

Full Article


Intravitreal injection
Oct 21, 2009
Bilateral same-day injection of anti-VEGF agents appears to be a safe management strategy for age-related macular degeneration presenting in both eyes. Bilateral presentation of wet AMD is not an uncommon problem, but scheduling staggered injections may prove challenging, Sundeep Dev, MD, said at Retina Congress 2009. In a retrospective...

Full Article


Lucentis
Oct 16, 2009
A case report of worsening of ocular ischemic syndrome following Lucentis (ranibizumab) administration is reported It has been recently documented that Lucentis causes retinal arteriolar vasoconstiction, and this has the potential to induce or worsen retinal ischemia (oxygen deprivation). It has been suggested that anti-VEGF agents be used with...

Full Article


Angioid streaks
Oct 15, 2009
A case report of worsening of angoid streaks in a patient following tresatment of associated choroidal neovascularization (CNV) with Avastin (bevacizumab) is presented. Angioid streaks are cracks in Bruch's membrane (the membrane that seperates the retina from the choroid), and are seen in association with a variety of systemic medical...

Full Article


Lucentis
Sep 25, 2009
Lucentis (ranibizumab) had a beneficial effect on visual outcome, along with safe and well-tolerated results, in treating neovascular age-related macular degeneration (AMD), according to the SAILOR study. The SAILOR study was a phase IIIb follow-up study to the MARINA and ANCHOR studies to evaluate the long-term safety and efficacy of Lucentis...

Full Article


Lucentis
Sep 22, 2009
Intravitreal Lucentis (ranibizumab) may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration (AMD), according to a new research report. Methods and Results In this prospective study involving 11 patients with previously untreated neovascular AMD, all eyes had 3 monthly IVT injections of...

Full Article


thermometer
Sep 17, 2009
A paper reports on two cases of fever following anti-VEGF injection. In the first case, a 76-year-old woman in good general health developed a fever (38.5-39.5° C) and chills 2-4 days following intravitreal injection of Avastin (bevacizumab) for age-related macular degeneration (AMD). The visual acuity was stable during the fever without...

Full Article


Lucentis
Feb 11, 2009
A meta-analysis of data from three large clinical studies finds that intravitreal injection of Lucentis (ranibizumab) is associated with increased risk of stroke, also known as cerebrovascular accident (CVA). Lucentis has revolutionized the treatment of age-related macular degeneration (AMD), yet there is concern about possible systemic...

Full Article


SELECT PAGE
First <<  1 2 3 4   >> Last
Most Popular
Less - past - More